ArticleActa obstetricia et gynecologica Scandinavica2026
Central sensitization in patients with chronic pelvic pain resistant to hormonal therapy: A cross-sectional study of prevalence and clinical correlates in a tertiary referral cohort.
Article in Acta obstetricia et gynecologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionChronic pelvic pain (CPP) affects over 25% of women, with endometriosis being a predominant cause. Central sensitization, particularly pelvic and perineal pain central sensitization (PPCS), is increasingly recognized as a key mechanism in CPP, yet its prevalence and clinical implications across the broader CPP population are underexplored. MATERIAL AND
methodsThe aim was to determine the prevalence of PPCS among patients with CPP unresponsive to hormonal therapy and to assess its impact on symptomatology, analgesic consumption, and quality of life. This retrospective study included 270 consecutive patients presenting for the first time with CPP resistant to hormonal therapy, with or without endometriosis, at a tertiary referral center in France (2024-2025). PPCS was defined using the Convergences PP criteria (score ≥5), and neuropathic-like features using the DN4 score (≥4). Data collected included pain features, comorbid symptoms, quality of life (EHP-5), history of violence, and prior treatments. Multivariable logistic and linear regression analyses were conducted to assess associations with analgesic use and EHP-5 scores.
resultsPPCS was present in 54.4% of patients and associated with more severe, multisystem symptoms, including urinary, gastrointestinal, and sexual dysfunction. Patients with PPCS had significantly higher use of strong analgesics (adjusted OR 2.48, 95% CI: 1.05-5.83, p = 0.038) and markedly impaired quality of life (+5.19 EHP-5 points, p < 0.001). A history of gender-based violence, reported by 25.9% of patients, was independently associated with higher analgesic consumption (aOR 2.56, p = 0.028) and was more prevalent among those with PPCS. Neuropathic-like features were associated with lower quality of life but not with increased analgesic use.
conclusionsThese findings support routine screening for central sensitization and trauma history in gynecological practice and advocate for multidisciplinary, trauma-informed, and neuromodulation-focused approaches to CPP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.